MetLife Investment Management’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $168K | Buy |
127,090
+10,902
| +9% | +$19.5K | ﹤0.01% | 2313 |
|
|
2025
Q4 | $217K | Sell |
116,188
-20,728
| -15% | -$39.8K | ﹤0.01% | 2232 |
|
|
2025
Q3 | $175K | Sell |
136,916
-29,076
| -18% | -$39.4K | ﹤0.01% | 2394 |
|
|
2025
Q2 | $206K | Buy |
165,992
+22,561
| +16% | +$26.1K | ﹤0.01% | 2175 |
|
|
2025
Q1 | $169K | Sell |
143,431
-1,948
| -1% | -$2.99K | ﹤0.01% | 2285 |
|
|
2024
Q4 | $266K | Buy |
145,379
+25,216
| +21% | +$49.2K | ﹤0.01% | 2152 |
|
|
2024
Q3 | $204K | Sell |
120,163
-33,996
| -22% | -$55.9K | ﹤0.01% | 2278 |
|
|
2024
Q2 | $211K | Buy |
154,159
+32,858
| +27% | +$66.4K | ﹤0.01% | 2208 |
|
|
2024
Q1 | $455K | Sell |
121,301
-10,494
| -8% | -$61.4K | ﹤0.01% | 1729 |
|
|
2023
Q4 | $1.29M | Hold |
131,795
| – | – | 0.01% | 1168 |
|
|
2023
Q3 | $1.1M | Hold |
131,795
| – | – | 0.01% | 1179 |
|
|
2023
Q2 | $1.75M | Buy |
131,795
+1,753
| +1% | +$21.3K | 0.01% | 986 |
|
|
2023
Q1 | $1.51M | Buy |
130,042
+12,183
| +10% | +$121K | 0.01% | 1016 |
|
|
2022
Q4 | $964K | Hold |
117,859
| – | – | 0.01% | 1229 |
|
|
2022
Q3 | $684K | Hold |
117,859
| – | – | 0.01% | 1408 |
|
|
2022
Q2 | $521K | Buy |
117,859
+13,893
| +13% | +$84.4K | ﹤0.01% | 1632 |
|
|
2022
Q1 | $946K | Buy |
103,966
+34,699
| +50% | +$400K | 0.01% | 1366 |
|
|
2021
Q4 | $1.42M | Hold |
69,267
| – | – | 0.01% | 982 |
|
|
2021
Q3 | $1.77M | Hold |
69,267
| – | – | 0.02% | 915 |
|
|
2021
Q2 | $2.42M | Buy |
69,267
+2,554
| +4% | +$74.3K | 0.02% | 790 |
|
|
2021
Q1 | $2.22M | Sell |
66,713
-5,088
| -7% | -$178K | 0.02% | 825 |
|
|
2020
Q4 | $1.86M | Hold |
71,801
| – | – | 0.02% | 863 |
|
|
2020
Q3 | $709K | Buy |
71,801
+6,448
| +10% | +$37.1K | 0.01% | 1199 |
|
|
2020
Q2 | $225K | Hold |
65,353
| – | – | ﹤0.01% | 1838 |
|
|
2020
Q1 | $200K | Buy |
65,353
+16,197
| +33% | +$66.3K | ﹤0.01% | 1696 |
|
|
2019
Q4 | $253K | Sell |
49,156
-17,636
| -26% | -$89.6K | ﹤0.01% | 1848 |
|
|
2019
Q3 | $345K | Hold |
66,792
| – | – | ﹤0.01% | 1626 |
|
|
2019
Q2 | $404K | Buy |
66,792
+9,086
| +16% | +$63.7K | ﹤0.01% | 1607 |
|
|
2019
Q1 | $417K | Hold |
57,706
| – | – | ﹤0.01% | 1572 |
|
|
2018
Q4 | $427K | Hold |
57,706
| – | – | 0.01% | 1463 |
|
|
2018
Q3 | $312K | Sell |
57,706
-1,041
| -2% | -$4.47K | ﹤0.01% | 1834 |
|
|
2018
Q2 | $209K | Hold |
58,747
| – | – | ﹤0.01% | 1901 |
|
|
2018
Q1 | $120K | Buy |
58,747
+45,502
| +344% | +$118K | ﹤0.01% | 2129 |
|
|
2017
Q4 | $35K | Buy |
+13,245
| New | +$46.4K | ﹤0.01% | 2217 |
|
Other funds holding PACB
AIM
VCM
NAMA
MetLife Investment Management's PACB Position: Q1 2026 in Review
MetLife Investment Management increased its Pacific Biosciences (PACB) stake by 9.4% in Q1 2026, buying an estimated $19.5K and bringing the position to 127,090 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #2313.
MetLife Investment Management first reported a position in PACB in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.42M in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- MetLife Investment Management held 127,090 shares of Pacific Biosciences worth $168K as of Q1 2026.
- MetLife Investment Management bought 10,902 Pacific Biosciences shares in Q1 2026, an estimated $19.5K.
- Pacific Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2313 holding.
- MetLife Investment Management first reported a position in Pacific Biosciences in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Pacific Biosciences position peaked at $2.42M in Q2 2021.
- 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.